ABL1 and acute lymphoblastic leukemia: In the ALL group (Supplementary Fig. S10), there was no significant difference among the subgroups (P = 0.855), and the 30-day survival rates of ‘B-lymphoblastic leukaemia with BCR-ABL1’, ‘B-lymphoblastic leukaemia, not otherwise specified (B-ALL, NOS)’, and ‘T-lymphoblastic leukaemia (T-ALL)’ groups were 95.1% (95% CI, 90.8–99.3%), 90.9% (95% CI, 85.1–96.6%), and 92.9% (95% CI, 87.7–98.0), respectively.